Connect with us

Technologies

Ivermectin and COVID-19: Why poison centers are getting calls about this controversial drug

Is this a miracle pill or a sham?

Since the start of the COVID-19 pandemic, some medical professionals have reviewed already available drugs to see if they could be used as effective treatments. Ivermectin, an anti-parasitic, was administered to some patients across the globe, with seemingly positive effects. However, more studies show it has little to no effect when it comes to treating COVID-19. There’s also been an increase in calls to poison centers by people who are taking ivermectin intended for animals.

On one side, there are doctors who say ivermectin could help end the pandemic if used globally. On the other are public health officials who have reviewed the data and say the drug’s effectiveness against COVID-19 isn’t conclusive.

Here’s everything you need to know about ivermectin and its use for COVID-19.

What is ivermectin?

Ivermectin is an anti-parasitic medicine «that works by altering cellular channels,» said Dr. Soumi Eachempati, CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College. The drug inhibits some viruses from infecting cells, thus preventing the virus from spreading. Ivermectin is usually given to treat parasitic infections like lice and Strongyloides, according to Eachempati.

Scientists at pharmaceuticals giant Merck discovered ivermectin in 1975 and began to use it to treat scabies, river blindness and other parasitic diseases carried by worms and lice starting in 1981. It’s on the World Health Organization’s list of essential medicines for a basic health care system. More than 250 million people take the drug across the globe each year, and it’s effective for animals as well.

The drug is considered safe when taken in appropriate dosages. Side effects for the ivermectin vary depending on whether it’s taken orally to treat intestinal infections or topically for skin infections. Oral tablets can cause drowsiness, nausea, vomiting and, in very rare cases, an increase in heart rate and seizures. Side effects for the topical ivermectin can include skin rash and irritation, while dry skin and stinging pain are severe and rare.

Can ivermectin be used to cure COVID-19?

This is where things get complicated. Public health agencies, including the Federal Drug Administration, the National Institutes of Health and the World Health Organization, don’t suggest ivermectin’s use to treat COVID-19. They cite the lack of data from large, randomized trials confirming the drug’s effectiveness to treat the disease.

Doctors who cited multiple smaller studies and firsthand experience say otherwise. They claim ivermectin does work to prevent people from developing symptoms from COVID-19 and can shorten recovery time for those already infected.

What do the public health agencies say about ivermectin use for COVID-19 treatment?

The FDA said in March it hasn’t approved the use of ivermectin to treat COVID-19. It warned that large doses of the drug are «dangerous and can cause serious harm.» The agency also advised against human use of ivermectin produced for animals, such as cows and horses, as the doses aren’t the same and could contain ingredients intended only for animals.

window.CnetFunctions.logWithLabel(‘%c One Trust ‘, «Service loaded: script_twitterwidget with class optanon-category-5»);

A growing number of people have been taking ivermectin for animals as word’s spread on social media about its possible use against COVID-19. This has resulted in some people calling state poison centers after taking the drug, since the medication is intended for animals. On Aug. 20, the Mississippi State Department of Health sent out an alert regarding the number of calls its poison center received, with 70% related to the «ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers.»

In April, the FDA reaffirmed in a post on its website that ivermectin isn’t approved to treat COVID-19 nor has it been given emergency use authorization.

The NIH said in February there was insufficient data to «recommend either for or against the use of ivermectin for the treatment of COVID-19.» It did say lab tests found the drug stopped the reproduction of the SARS-CoV-2 virus that cause the disease. However, to be effective, the dosages would need to be «100-fold higher than those approved for use in humans.»

While some clinical studies showed ivermectin to have no benefit, the NIH said others saw a lower mortality rate among patients. However, those studies were incomplete or had methodological limitations such as small sample sizes or patients receiving additional medicine along with ivermectin, according to the NIH.

The WHO said in March the current evidence on the use of ivermectin for treatment of COVID-19 was «inconclusive.»

A doctor in Arkansas who prescribed the drug to patients is under investigation by the state medical board, according to a report from CNN. He reportedly gave ivermectin prescriptions to prisoners at the county jail where he was contracted to provide medical services.

Who says ivermectin is a treatment, and what information do they have?

Ivermectin’s potential use as a COVID-19 therapeutic made headway last December during a Senate Homeland Security Committee meeting called Focus on Early Treatment of COVID-19. Dr. Pierre Kory, a pulmonary and critical care specialist, testified about the drug’s usage for treatment of the disease.

«Ivermectin is highly safe, widely available, and low cost,» Kory said in the Senate meeting. «We now have data from over 20 well-designed clinical studies, 10 of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. These data show that ivermectin is effectively a ‘miracle drug’ against COVID-19.»

During his testimony, Kory referred to a paper he authored — Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 — that was published in the May edition of the American Journal of Therapeutics.

The paper was also included in the Frontiers of Pharmacology journal in January but was then removed in March. Dr. Frederick Fenter, chief executive editor of the journal, said the paper was removed due to «strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.» Fender also said the authors promoted their own specific ivermectin-based treatment, which goes against editorial policies.

A study listed in Kory’s paper involved giving ivermectin to 234 uninfected health care workers in Argentina and found those who received the drug were far less likely to be diagnosed with COVID. For mildly ill patients, an Iraq study saw a quicker recovery time.

There are also studies that show otherwise. A clinical trial of 476 patients found ivermectin didn’t improve the recovery time in patients who had COVID-19. A review of 10 random clinical trials, with more than 1,000 participants, also didn’t find improvements with ivermectin. One Egyptian study claimed to show positive results, but it’s since been redacted over ethical concerns. Another study, of 1,500 patients, found that ivermectin had «no effect whatsoever.»

Merck, the company that discovered ivermectin, released a statement in February saying there was «no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies» and «no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease.» It also cited a lack of safety data from major studies.

Why is there controversy over ivermectin?

The debate about ivermectin’s usage to treat COVID-19 has gone from the hospital to social media, exacerbating the discourse as well as the vitriol. While those in support of the drug appear to want an end to the pandemic, their arguments in favor of ivermectin have become fodder for anti-vaxxers and conspiracy theorists.

Groups that have spread misinformation about COVID-19 throughout the pandemic latched onto ivermectin’s usage following Kory’s Senate testimony. Anti-vax groups on Telegram share misinformation about the vaccine while asking where they can buy the drug. Rumble, an alternative video platform to YouTube, has pages of videos falsely saying vaccines are ineffective while advising people to also take ivermectin.

Anti-vax posts and videos can also be found on YouTube, Facebook and Twitter, although the companies are attempting to take these posts down or make them harder to find.

Kory was a guest on the Dark Horse Podcast hosted by Bret Weinstein, a former professor at Evergreen State College, on June 1 to talk about ivermectin. That video was eventually demonetized on YouTube and Weinstein’s channel received a strike, which prevented him from posting content for one week and could lead to its removal if he receives two more strikes within 90 days.

YouTube says its actions on Weinstein’s videos were part of its policies.

«While we welcome open discussions of potential treatments and clinical trials related to COVID-19 on YouTube, based on guidance from the CDC, FDA and other local health authorities, we don’t currently allow content that recommends ivermectin as an effective treatment or prevention method for the virus,» said Ivy Choi, a YouTube spokesperson. «We craft our policies to prevent the risk of egregious real-world harm, and update them as official guidance evolves. We do allow exceptions to our policy about ivermectin, including content that also gives viewers the full context of the FDA’s current position.»

Because of YouTube’s decision, the controversy over ivermectin grew and became tied to what some claim to be «big tech censorship.»

What is required for ivermectin to get approved for COVID-19 treatment?

For the public health agencies, it’s going to come down to the results of large clinical studies being conducted around the world.

«In the UK, it was announced that ivermectin will be added to the Principle Trial, a large clinical study designed to assess potential COVID therapies for non-hospitalized therapies for patients at higher risk for severe disease,» said Dr. David Shafran, head of pediatrics at telehealth app K Health. «This should demonstrate more definitively the efficacy of ivermectin in early-stage COVID infections. Fingers crossed because it’s a cheap medication with a good safety profile. It would be great to add this to the armament of medication to fight COVID.»

The Oxford University Principle Trial has more than 5,000 participants and will give a three-day course of oral ivermectin treatment to individuals randomly and compare their results to individuals who will receive standard care.

In the US, the NIH is evaluating therapeutics for COVID-19 with its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol. ivermectin was added in phase three of ACTIV-6, which will test the effectiveness of repurposed drugs.

«The ACTIV prioritization group, trial team and trial oversight groups continuously track new data on any agent we are studying in our trials and evaluate that data for how it might influence our testing of that agent and the safety/well being of the participants in the trial,» said Dr. Sarah Dunsmore, a program director at the National Center for Advancing Translational Sciences that is part of the NIH.

What’s unclear is how long the whole process will take. The studies need time to be completed, and then the agencies will require additional time to come up with decisions based on the data.

Related Topics:

Technologies

The Apple Watch Series 12 Could Bring Back a Throwback iPhone Feature

Everything we’ve heard so far about the rumored Apple Watch Series 12.

We’re hot off a busy March Apple launch with seven new products, including an iPhone 17E, updated MacBook Pros and a colorful MacBook Neo that’s about to rattle the Chromebook market. As we set our sights on the next big hardware launch, the Apple Watch Series 12 is already on the horizon.

While there haven’t been any concrete leaks yet, there’s plenty we can infer based on Apple’s past launches and typical release patterns. There are also a few lingering rumors that could finally land this year, including a possible nod to a long-removed but not forgotten iPhone feature.

Apple Watch Series 12 launch date

If there’s one thing Apple tends to keep consistent, it’s the timing of its fall hardware event, where it typically unveils its newest flagship iPhones and Apple Watch models.

Apple typically holds this event on the second Tuesday of September (usually the week after Labor Day). By that logic, Sept. 15 seems like the most likely candidate for Apple’s 2026 fall event. Because it lands a bit later in the month than in previous years, there’s also a slim chance Apple moves it up to Sept. 9 (Labor Day week), as it has before.

As in previous years, preorders would likely open on the Friday after the event, with availability following a week or so later (assuming no production delays).

Pricing and availability

Expect pricing for the new watches to stay roughly in line with the current Series 11 lineup, which starts at about $400 (42mm Wi-Fi model). Though price hikes aren’t completely off the table, with lingering tariff increases and the potential for supply chain issues.

How many Apple Watch models will we get?  

A Series 12 is all but guaranteed — we’ve had a new Apple Watch model arrive every year since its launch. What’s less certain is whether Apple will refresh the entire lineup again this year. The Apple Watch SE and Ultra models don’t follow the same annual update cycle, and because both the SE 3 and Ultra 3 were refreshed in 2025, it’s less likely that Apple will update both again this year.

If Apple does add another model alongside the Series 12, the Ultra would be the more plausible candidate. Apple isn’t one to hold out on new features for its high-end models when warranted. Or if it follows the pattern set with the Ultra 2, the company might just roll out a new color model for the Ultra 3.

Design upgrades on the Apple Watch Series 12

There are rumblings of a redesign in the works, but given how sparse the chatter has been, my guess is we won’t see a major design overhaul this year. Expect the same silhouette, similar colors and materials. What could change: screen technology. A more energy-efficient display — potentially an improved LTPO panel with better brightness, as seen on the Series 10 — could help claw back some battery life without adding bulk.

Battery life and processor

The Series 11 and Ultra 3 got a significant battery bump over their predecessors: at least 6 hours more by Apple’s numbers and roughly an extra half day (or more) in my real-world testing. And the Ultra 3 also got charging speed worthy of its name, like its newer siblings. But there’s still a lot of room for improvement on both battery life and charging speed. 

With no major clues hinting at bigger batteries yet, I’d bet we see more incremental gains (if any) on the Series 12. Improvements could come from better screen technology, software optimizations, and more efficient processors. 

In theory, the processor name usually matches the watch number, suggesting an S12 chip this year. But since the Series 11 and Ultra 3 are still running on the previous year’s S10 chip, the next upgrade could technically be an S11, making this year’s naming a bit awkward.

New health features on the horizon

Apple has already dipped its toes into blood pressure monitoring with hypertension notifications on the Apple Watch (Series 10, Series 11 and Ultra 3). The feature alerts owners when it detects signs of abnormally high blood pressure, but it stops short of providing an on-the-spot read. This could be on the table for the fall of 2026.

Other wearable health companies like Omron and Med-Watch have proven that wrist-based blood pressure measurement is possible, though it’s not as reliable as a traditional cuff and may require new (bulkier) hardware to bring to the Apple Watch. 

According to Bloomberg’s Mark Gurman, Apple has been testing the feature internally but has encountered accuracy issues. And even if Apple pulls it off for this year, it might measure only baseline trends similar to Samsung’s blood pressure feature on the Galaxy Watch 7 and Ultra (not supported in the US). 

Glucose monitoring is another long-running rumor that’s on the table, but according to Gurman, it’s even further from a finished product than blood pressure and realistically wouldn’t appear before 2027.

Biometric authentication: Touch ID or Face ID?

Rumors of a camera on the Apple Watch have been around for a few years — not for selfies, but potentially for Face ID or AI-based image recognition. 

Apple Intelligence on the iPhone introduced a visual search tool that uses the camera to identify objects and places in real time, and it might be a matter of time before this feature eventually makes its way to the wrist. Meanwhile, wearable-focused processors like Qualcomm’s Snapdragon chips already support cameras and even livestreaming. Apple is known to use its proprietary chips, so it’s unlikely this would impact Apple’s timeline, but it shows the technology is there, and we may see it down the line on the Apple Watch. Just not this year, according to Bloomberg.

A more feasible near-term option could be Touch ID. Macworld recently spotted lines of internal code suggesting Apple has been experimenting with biometric authentication for the 2026 Apple Watch lineup. According to the report, the code references «AppleMesa,» which is Apple’s internal code name for a watch-based Touch ID. It’s still unclear whether the sensor would be integrated under the display, like we see on Android phones, or built into the side button or the Digital Crown. 

Watch OS 27 wishlist 

Now that Apple has standardized its operating system names to match the year ahead, you don’t need to be a rocket scientist to figure out that the next big update for the Apple Watch will be WatchOS 27. 

With a major redesign already in the books (5 New Apple Watch Features Coming With WatchOS 26), we’re not expecting a dramatic visual change this time around, but there’s plenty on the wishlist, including better battery management tools and more customizable gesture controls. Apple could also expand Workout Buddy from metric-driven encouragement into more concrete training territory. This could bring it closer to what Samsung is trying with its AI-powered Running Coach.

Lastly, I’d welcome a more robust symptom tracker tied into the Vitals app similar to Oura Ring’s Symptom Radar that can flag early signs of illness. 

Other Health app updates 

The next version of WatchOS 27 could also bring changes to the Health app. According to a report from Mark Gurman at Bloomberg, Apple has been working on a top-secret initiative code-named Project Mulberry, aimed at revamping the Health app with an AI-powered health concierge that could unify your health, fitness, and medical data in one place.

However, the project has recently run into some obstacles. Bloomberg’s latest report suggests Apple has put the effort on hold (at least for this year). That still leaves room for improvement on the Health app front with a potential redesign to the main dashboard that would make spotting trends easier. 

Continue Reading

Technologies

Today’s NYT Connections: Sports Edition Hints and Answers for March 10, #533

Here are hints and the answers for the NYT Connections: Sports Edition puzzle for March 10, No. 533.

Looking for the most recent regular Connections answers? Click here for today’s Connections hints, as well as our daily answers and hints for The New York Times Mini Crossword, Wordle and Strands puzzles.

Today’s Connections: Sports Edition features a lot of team names, but that doesn’t mean it’s an easy one to solve. If you’re struggling with today’s puzzle but still want to solve it, read on for hints and the answers.

Connections: Sports Edition is published by The Athletic, the subscription-based sports journalism site owned by The Times. It doesn’t appear in the NYT Games app, but it does in The Athletic’s own app. Or you can play it for free online.

Read more: NYT Connections: Sports Edition Puzzle Comes Out of Beta

Hints for today’s Connections: Sports Edition groups

Here are four hints for the groupings in today’s Connections: Sports Edition puzzle, ranked from the easiest yellow group to the tough (and sometimes bizarre) purple group.

Yellow group hint: Play ball!

Green group hint: Not front.

Blue group hint: Certain NFL player.

Purple group hint: They play at Smoothie King Center.

Answers for today’s Connections: Sports Edition groups

Yellow group: An AL Central player.

Green group: Words appearing before «back,» in football.

Blue group: Associated with Derrick Henry.

Purple group: New Orleans Pelicans.

Read more: Wordle Cheat Sheet: Here Are the Most Popular Letters Used in English Words

What are today’s Connections: Sports Edition answers?

The yellow words in today’s Connections

The theme is an AL Central player. The four answers are Guardian, Royal, Tiger and Twin.

The green words in today’s Connections

The theme is words appearing before «back,» in football. The four answers are corner, defensive, full and running.

The blue words in today’s Connections

The theme is associated with Derrick Henry. The four answers are Heisman, King, Ravens and Titans.

The purple words in today’s Connections

The theme is New Orleans Pelicans. The four answers are Bey, Fears, Murphy and Queen.

Continue Reading

Technologies

Today’s NYT Mini Crossword Answers for Tuesday, March 10

Here are the answers for The New York Times Mini Crossword for March 10.

Looking for the most recent Mini Crossword answer? I’d just like to point out that the New York Times puzzle-makers love the 7-Across answer — they use it about every other week. Click here for today’s Mini Crossword hints, as well as our daily answers and hints for The New York Times Wordle, Strands, Connections and Connections: Sports Edition puzzles.

Need some help with today’s Mini Crossword? Read on. And if you could use some hints and guidance for daily solving, check out our Mini Crossword tips.

If you’re looking for today’s Wordle, Connections, Connections: Sports Edition and Strands answers, you can visit CNET’s NYT puzzle hints page.

Read more: Tips and Tricks for Solving The New York Times Mini Crossword

Let’s get to those Mini Crossword clues and answers.

Mini across clues and answers

1A clue: Writing that lacks substance
Answer: FLUFF

6A clue: Pencil in a cosmetics bag
Answer: LINER

7A clue: ___ acid (building block of proteins)
Answer: AMINO

8A clue: Partner of services, in economics
Answer: GOODS

9A clue: Small criticism
Answer: NIT

Mini down clues and answers

1D clue: Warning sign in a relationship, metaphorically
Answer: FLAG

2D clue: Fancy prom ride
Answer: LIMO

3D clue: SAG-AFTRA, for one
Answer: UNION

4D clue: Luxury fashion house headquartered in Rome
Answer: FENDI

5D clue: Ground coating on a cold morning
Answer: FROST

Continue Reading

Trending

Copyright © Verum World Media